• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Regeneron To Invest $2B In New Saratoga Springs Production Plant

    FIERCE PHARMA

    Regeneron Ph2 Factor XI Antibodies Show Antithrombotic Effect

    GLOBENEWSWIRE

    Dupixent Study Meets Endpoints; sBLA Under FDA Priority Review

    PRESS RELEASE

    Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins

    BUSINESSWIRE

    Regeneron Announces Investor Conference Presentations

    GLOBENEWSWIRE

    Dupixent Secures 2025 Prix Galien USA Best Biotech Product Award

    GLOBENEWSWIRE

    Regeneron Pledges $1B+ For Modex Multispecific Antibodies

    FIERCE BIOTECH

    Regeneron Unveils Q3 2025 Financial Results

    GLOBENEWSWIRE

    FDA Rejects Eylea HD For Ongoing Manufacturing Issues

    FIERCE PHARMA

    Zag Bio Emerges With $80M Funding For Tregs Diabetes Candidate

    FIERCE BIOTECH

    Regeneron Scraps 2Seventy`s CAR T For Lymphoma In Strategic Move

    BIOSPACE

    Rising Stars: Kristen Raimondi On Creating New Hope For Patients

    FIERCE PHARMA

    Regeneron, Celltrion Shake Hands On Eylea Biosimilar Settlement

    FIERCE PHARMA

    Libtayo Recommended by CHMP for Adjuvant CSCC in EU

    GLOBENEWSWIRE

    Regeneron, Sanofi Receive 1- To 2-Month Priority Review Vouchers

    FIERCE BIOTECH

    Regeneron Shows Advances in Oncology Portfolio & Pipeline at ESMO

    GLOBENEWSWIRE

    Novo Plant Issues May Mean Delays For Regeneron, Scholar Rock

    FIERCE PHARMA

    DB-OTO Show Dramatic Hearing Improvements In Genetic Hearing Loss

    GLOBENEWSWIRE

    FDA Expands Regeneron`s Libtayo Treatment for Skin Cancer

    REUTERS

    Regeneron To Present Q3 2025 Results, Host Conference On Oct 28

    GLOBENEWSWIRE

    Evkeeza Approval For Ultra-Rare Pediatric High Cholesterol

    GLOBENEWSWIRE

    Sanofi`s Dupixent® For Chronic Spontaneous Urticaria Gains

    GLOBENEWSWIRE

    Sanofi, Regeneron`s Dupixent For Chronic Spontaneous Urticaria

    GLOBENEWSWIRE

    Regeneron Donates Ebola Treatment to High-Risk Countries

    GLOBENEWSWIRE

    Regeneron`s Rare Bone Disorder Drug Succeeds in Late-Stage Trial

    REUTERS

    Sanofi`s Libtayo Combo Shows 5-Year Survival Gain in NSCLC

    INDPHARMAPOST

    Targeted Myasthenia Gravis Therapies Flood Sparse Market

    BIOSPACE

    Sandoz to Launch Eylea Biosimilar in Late 2026 After Settlement

    FIERCE PHARMA

    Libtayo Plus Chemo Shows 5-Year Survival in Advanced Lung Cancer

    GLOBENEWSWIRE

    Regeneron Antibodies Triumph in Ph. 3 Cat, Pollen Allergy Trials

    FIERCE BIOTECH

    Regeneron Adjusts Presentation Time at Investor Conference

    GLOBENEWSWIRE

    Regeneron Plans 2026 FDA Filing for siRNA Myasthenia Gravis Drug

    BIOSPACE

    Regeneron`s Immune Disorder Therapy Improves Functions in Trial

    REUTERS

    Regeneron Reports Ph3 Success in Generalized Myasthenia Gravis

    GLOBENEWSWIRE

    FDA Delays 2 Decisions on Eylea HD Due to Manufacturing Issues

    FIERCE PHARMA

    Regeneron Announces Investor Conference Presentations

    GLOBENEWSWIRE

    Onco360® to Partner as Specialty Pharmacy for Lynozyfic

    GLOBENEWSWIRE

    FDA Declines to Approve Regeneron`s Blood Cancer Drug

    REUTERS

    Regeneron Unveils Strong Q2 2025 Financial and Operating Results

    GLOBENEWSWIRE

    Issues at Novo Nordisk`s Indiana site trip up Regeneron again

    FIERCE PHARMA

    Regeneron Reveals 2025 Creative Innovation Prize Winners

    GLOBENEWSWIRE

    US FDA Approves Regeneron`s Blood Cancer Therapy

    PRESS RELEASE

    Regeneron`s Biologics Lynozyfic Receive Approval in US

    FDA

    Regeneron to Report Q2 Results on August 1

    GLOBENEWSWIRE

    Regeneron Launches Donation Matching Program with Charity

    GLOBENEWSWIRE

    Regeneron Backs Off 23andMe, Losing Bid to Former CEO

    BIOSPACE

    Dupixent Beats Xolair in Ph4 Nasal Polyp Study at EAACI 2025

    PRESS RELEASE

    Regeneron Says Weight-Loss Drug Helped Preserve Muscle Mass

    REUTERS

    Regeneron Expands Clinical-Stage Obesity Portfolio

    PRESS RELEASE

    Libtayo Phase 3 Data in Adjuvant Treatment of High-Risk Carcinoma

    GLOBENEWSWIRE

    Linvoseltamab Combos Show Early Results In R/R Myeloma

    GLOBENEWSWIRE

    AI Genomics Breakthrough Aligns with Regeneron’s 23andMe Buyout

    GLOBENEWSWIRE

    Viz.ai Collaborates With Sanofi and Regeneron on COPD Care

    PRESS RELEASE

    Regeneron to Acquire 23andMe in Court-Supervised Sale

    GLOBENEWSWIRE

    Regeneron plans to buy 23andMe for $256M

    ENDPTS

    Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit

    FIERCE PHARMA

    Teen Scientists Win $9M+ at 2025 Regeneron ISEF

    GLOBENEWSWIRE

    Dupixent® Data at ATS Show Benefits in Type 2 Lung Inflammation

    GLOBENEWSWIRE

    Regeneron to Highlight ASCO Advances with Libtayo Updates

    GLOBENEWSWIRE

    Regeneron`s first-quarter results miss on lower Eylea demand

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.